Gliptins and Glitazones Aren't Associated with Adverse Cardiovascular Outcomes in Type 2 Diabetics

Summary and Comment |
August 25, 2016

Gliptins and Glitazones Aren't Associated with Adverse Cardiovascular Outcomes in Type 2 Diabetics